Astec LifeSciences Limited has informed the Exchange about Copy of Newspaper Publication
ASTEC · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astec LifeSciences Limited has submitted copies of the newspaper advertisement of its Q1 FY26 (quarter ended 30 June 2025) unaudited financial results, published on 29 July 2025 in Business Standard (English) and Mumbai Lakshadeep (Marathi), as required under SEBI Listing Regulations. The Board had approved these results on 28 July 2025. Total revenue from operations rose to Rs. 9,158.86 lakhs in Q1 FY26, up from Rs. 7,029.62 lakhs in Q1 FY25, a growth of roughly 30% year-on-year. Despite the revenue growth, the company continued to post a net loss of Rs. 3,302.69 lakhs in Q1 FY26, although this was an improvement from the Rs. 3,971.54 lakhs loss in the same quarter last year. Basic and diluted EPS stood at Rs. (16.85) versus Rs. (20.26) in Q1 FY25. The balance sheet shows outstanding debt of Rs. 59,446.71 lakhs against a net worth of Rs. 20,180.95 lakhs, implying a debt-equity ratio of 2.95.
This is a procedural regulatory filing (newspaper republication of already-disclosed Q1 results), so it is unlikely to move the stock on its own. The underlying numbers — improving revenue, narrowing losses but persistent bottom-line weakness and high leverage — were already in the market after the 28 July board announcement, and investors should focus on the company's path to profitability and debt reduction.